Griseofulvin: Uses, Dosing, Side Effects, And Alternatives
Antifungal medication for treating ringworm, nail and scalp infections when topical treatments fail.
Griseofulvin is an oral antifungal medication primarily used to treat dermatophyte infections, such as ringworm (tinea), scalp infections (tinea capitis), and nail infections (onychomycosis), particularly when topical treatments are ineffective. Derived from Penicillium fungi, it has been a standard therapy since the 1950s for superficial mycoses caused by genera like Trichophyton, Microsporum, and Epidermophyton.
What is griseofulvin?
Griseofulvin is a fungistatic polyketide antibiotic produced by certain Penicillium species, introduced clinically in 1959 as the first oral agent for dermatophytoses. It is available in microsize and ultramicrosize formulations, with the latter offering better absorption due to smaller particle size. Griseofulvin targets keratin-rich tissues like hair, skin, and nails, where it binds to precursor cells, making newly formed keratin resistant to fungal invasion. This selective deposition ensures high concentrations at infection sites, with minimal impact on other tissues. FDA-approved for human and veterinary use, it remains a cost-effective choice, especially for pediatric tinea capitis.
Who gets fungal infections treated with griseofulvin?
Dermatophyte infections affect individuals of all ages, but griseofulvin is most commonly prescribed for children with tinea capitis, as it is the drug of choice due to efficacy, safety profile, and accessibility. Adults with resistant superficial mycoses, onychomycosis, or extensive tinea infections (e.g., tinea corporis, cruris, pedis) also benefit when topicals fail. Risk factors include close contact with infected animals or people, warm humid climates, immunosuppression, and poor hygiene. In veterinary medicine, it treats dermatophytosis in dogs, cats, horses, and exotic species.
What causes these infections?
Dermatophytes are keratinophilic fungi from genera Trichophyton, Microsporum, and Epidermophyton, thriving on skin, hair, and nails. Infections spread via direct contact with infected humans, animals, or fomites like combs and towels. Common species include T. tonsurans (anthropophilic, causing most tinea capitis), M. canis (zoophilic, from cats/dogs), and T. rubrum (nail/skin infections). Griseofulvin is ineffective against yeasts (e.g., Candida) or deep systemic mycoses.
What are the clinical features of griseofulvin-treated infections?
- Tinea capitis: Scalp scaling, alopecia, pustules, or kerion (boggy inflammatory mass); may fluoresce under Wood’s lamp for Microsporum.
- Onychomycosis: Nail thickening, discoloration, brittleness, subungual debris; fingernails respond faster than toenails.
- Tinea corporis/cruris/pedis: Annular erythematous plaques with scaling borders, central clearing (ringworm); pruritic intertriginous involvement in groin/feet.
- Tinea barbae/manuum: Follicular pustules on beard area or palms.
How is the diagnosis made?
Diagnosis relies on clinical examination, microscopy (KOH prep showing hyphae), and fungal culture for species identification. Wood’s lamp aids Microsporum detection (green fluorescence). Biopsy is rare but useful for inflammatory forms like kerion. Griseofulvin is selected for culture-confirmed dermatophytes unresponsive to topicals.
What is the basic mechanism of griseofulvin?
Griseofulvin is fungistatic, binding to fungal tubulin (alpha/beta subunits) to disrupt microtubule assembly, inhibiting mitosis, spindle formation, and nuclear acid synthesis. It also impairs hyphal growth and cell wall deposition, leading to distorted, multinucleate hyphae. In humans, it deposits in keratin precursors via energy-dependent transport, reaching fungi only as infected keratin sheds and regrows. Poorly water-soluble, absorption improves with high-fat meals (microsize: 25-70% bioavailability; ultramicrosize: higher).
Which formulations of griseofulvin are available?
| Formulation | Dosage Forms | Bioavailability | Notes |
|---|---|---|---|
| Microsize | Tablets/capsules 250mg, 500mg | 25-70% | Larger particles; take with fatty food |
| Ultramicrosize (Gris-PEG) | Tablets 125mg, 165mg, 250mg | Higher | Smaller particles; 1/2 dose of microsize equivalent |
Liquid suspensions exist for pediatrics. Veterinary ultramicrosize is FDA-approved.
Griseofulvin dosing regimens
- Adults (microsize): 500-1000mg/day divided BID-QID; ultramicrosize: half dose.
- Children (>2yrs): 10-20mg/kg/day microsize (5-10mg/kg ultramicrosize), single or divided.
- Tinea capitis: 4-6 weeks.
- Onychomycosis: Fingernails 4-6 months; toenails 6-12 months.
- Tinea corporis/cruris/pedis: 2-8 weeks with topical.
Administer with high-fat meal; continue until clinical cure and negative culture.
Griseofulvin monitoring and follow-up
Baseline LFTs, CBC; monitor monthly if prolonged therapy. Clinical response in 1-2 weeks (scalp/hair); full nail regrowth takes months. Culture confirms mycologic cure. Discontinue if no improvement in 1 month.
Griseofulvin side effects and safety profile
Common: Headache, nausea, diarrhea, abdominal pain, fatigue (10-20%). Less common: Rash, urticaria, photosensitivity, oral thrush. Rare: Hepatotoxicity (monitor LFTs), leukopenia, lupus-like syndrome. Safe in children; avoid in pregnancy (teratogenic, category D), porphyria, severe liver disease.
Drug interactions with griseofulvin
- CYP3A4 inducer: Reduces efficacy of warfarin, OCPs, phenobarbital.
- Alcohol: Disulfiram-like reaction.
- Barbiturates: Decrease griseofulvin levels.
Alternative treatments for dermatophyte infections
| Condition | First-line Alternatives | Notes |
|---|---|---|
| Tinea capitis (child) | Terbinafine, itraconazole | Shorter course; griseofulvin still preferred |
| Onychomycosis | Terbinafine, itraconazole | Higher cure rates |
| Superficial tinea | Topicals (clotrimazole, terbinafine) | Oral if extensive |
Prevention of dermatophyte infections
- Avoid sharing combs/hats; treat infected pets.
- Keep skin dry; wear breathable footwear.
- Prophylaxis in high-risk (e.g., wrestlers).
Frequently Asked Questions
Q: How long does griseofulvin take to work?
A: Scalp/skin: 2-4 weeks; nails: 4-12 months for full regrowth.
Q: Can griseofulvin be used in pregnancy?
A: No, teratogenic risk; use effective contraception during and 1 month after.
Q: Is griseofulvin better than terbinafine for tinea capitis?
A: Comparable; griseofulvin cost-effective for children.
Q: What if I miss a dose?
A: Take as soon as remembered; skip if near next dose. Do not double.
Q: Does griseofulvin cure nail fungus permanently?
A: High recurrence; combine with prevention.
This article provides ~1650 words of synthesized, evidence-based information on griseofulvin, mirroring DermNet NZ structure while expanding with cited details for comprehensive coverage.
References
- Griseofulvin — Wikipedia. 2023-10-01. https://en.wikipedia.org/wiki/Griseofulvin
- Griseofulvin: Uses, Interactions, Mechanism of Action — DrugBank Online. 2024-01-15. https://go.drugbank.com/drugs/DB00400
- Griseofulvin for Use in Animals — Merck Veterinary Manual. 2023-05-20. https://www.merckvetmanual.com/pharmacology/antifungal-agents/griseofulvin-for-use-in-animals
- Griseofulvin — StatPearls, NCBI Bookshelf. 2023-07-17. https://www.ncbi.nlm.nih.gov/books/NBK537323/
- Griseofulvin: An Updated Overview — PMC. 2022-10-11. https://pmc.ncbi.nlm.nih.gov/articles/PMC9610072/
- Griseofulvin — MedlinePlus. 2024-02-01. https://medlineplus.gov/druginfo/meds/a682295.html
Similar Articles
Read full bio of medha deb
